Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

TY - JOUR

T1 - Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD

AU - Lipworth, Brian J.

AU - Kuo, Chris R. W.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].

AB - The pooled post hoc analysis of three randomised controlled trials by Vestbo et al. [1] found that combinations containing inhaled corticosteroid (ICS) significantly reduced non-respiratory-related mortality in chronic obstructive pulmonary disease (COPD) compared to long-acting bronchodilator therapies alone, the difference amounting to −35% (95% CI −57% to −3%). These studies did not adjudicate on cause of death and only followed patients for up to 1 year. In the IMPACT trial, all-cause mortality was 42% lower and cardiovascular attributed deaths were 52% lower when comparing triple therapy to combined long-acting bronchodilators over 1 year [2].

U2 - 10.1183/13993003.02420-2018

DO - 10.1183/13993003.02420-2018

M3 - Letter

C2 - 30765485

SN - 0903-1936

VL - 53

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - 2

M1 - 1802420

ER -